摘要
海马和杏仁核是阿尔茨海默病 (AD)发病早期易受攻击的大脑区域。然而,以往的研究主要集中于在AD病理中表征海马,而很少研究杏仁核。在这里,我们研究 了广泛应用于AD造模的年轻(2、3和4个月大)双转基因(Tg)APP/PS1小鼠海马和杏仁核中神经元的结构和功能。与野生型同窝小鼠相比,这三个年龄阶段的Tg 小鼠杏仁核占主导地位的记忆变差。而一直到4个月大,海马占主导地位的记忆保持完整。同样,2月龄Tg小鼠基底外侧杏仁核神经元的树突减少,而在海马CA1区和CA3区的神经元树突保持相对完整。年轻Tg小鼠杏仁核中脑源性神经营养因子信号转导通路(如AKT和PKC))减弱,而在在海马中不变。此外 5-HT 的降低和 Aβ水平的升高也较早出现在杏仁核内,并且比海马更为明显。5-HT和Aβ 之间的负相关在杏仁核是显而易见的,而在海马中并不存在这种对应关系。总之,这些结果表明,神经退行性疾病的早于海马发生在杏仁核中。我们认为,杏仁核的功能应该被应用作为诊断因AD引起的轻度认知功能障碍的认知筛查工具。
关键词: 阿尔茨海默病、杏仁核、树突、海马、学习记忆、可塑性。
Current Alzheimer Research
Title:Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Volume: 12 Issue: 10
Author(s): Tzu-Wei Lin, Yu-Fan Liu, Yao-Hsiang Shih, Shean-Jen Chen, Tung-Yi Huang, Chia-Yuan Chang, Chi-Hsiang Lien, Lung Yu and Shun-Hua Chen and Yu-Min Kuo
Affiliation:
关键词: 阿尔茨海默病、杏仁核、树突、海马、学习记忆、可塑性。
摘要: Both the hippocampus and amygdala are early vulnerable brain regions in the development of Alzheimer’s disease (AD). However, previous studies mainly focused on characterizing the hippocampus in the pathophysiology of AD, leaving the amygdala less explored. Here, we characterized the structures and functions of neurons in the hippocampus and amygdala of young (2, 3 and 4 months of age) APP/PS1 double transgenic (Tg) mice, a widely used AD mouse model. Compared to wild-type littermates (Wt ), Tg mice performed worse in amygdala-dominant memory at all three ages, while hippocampus-dominant memory remained intact until 4-month-old. Likewise, the dendritic arbors of neurons in the basolateral amygdala were reduced in Tg mice as early as 2-months-old, while the dendritic arbors of neurons in the hippocampal CA1 and CA3 regions were relatively intact. BDNF signaling pathways (e.g. AKT and PKC) were reduced in the amygdala, but not in the hippocampus, of young Tg mice. Furthermore, reduction of 5-HT and elevation of Aβ levels also occurred earlier in the amygdala and were more pronounced than those in the hippocampus. Negative correlations between the levels of 5-HT and Aβ were evident in the amygdala, but not in the hippocampus. Taken together, these results suggest that neurodegeneration occurs earlier in the amygdala than in the hippocampus. We suggest that amygdala function should be incorporated into the cognitive screening tool for the diagnosis of mild cognitive impairment due to AD.
Export Options
About this article
Cite this article as:
Tzu-Wei Lin, Yu-Fan Liu, Yao-Hsiang Shih, Shean-Jen Chen, Tung-Yi Huang, Chia-Yuan Chang, Chi-Hsiang Lien, Lung Yu and Shun-Hua Chen and Yu-Min Kuo , Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (10) . https://dx.doi.org/10.2174/1567205012666151027124938
DOI https://dx.doi.org/10.2174/1567205012666151027124938 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary Research Highlights (Amyloid β-Peptide and Alzheimer’s Disease: It’s All the RAGE)
CNS & Neurological Disorders - Drug Targets Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease
Current Alzheimer Research The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design The Integration of the Glutamatergic and the White Matter Hypotheses of Schizophrenias Etiology
Current Neuropharmacology P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!
CNS & Neurological Disorders - Drug Targets Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Therapeutic Potential of Multifunctional Tacrine Analogues
Current Neuropharmacology Streptozotocin-Induced Diabetes Mellitus in Neonatal Rats: An Insight into its Applications to Induce Diabetic Complications
Current Diabetes Reviews Patent on Biomarkers in Medical Research: A Focus on Neuropsychiatric Disorders
Recent Patents on Biomarkers The Concept of Phenoptosis and its Usefulness for Controlling Aging
Current Aging Science An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics